The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient. - Wikidata - awgldk - TriplyDB

The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.

The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.

http://www.wikidata.org/entity/Q37198266

about

Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems.RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine

P2860

Q38953629-AA7B29DC-D7BD-4E35-9A9A-01E8153B9EEA Q58759056-91A66D77-BAB2-4973-8AD1-2FFD97428DC6

P2860

The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.

http://www.wikidata.org/entity/Q37198266

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 December 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The relationship between RRM1 ...... apy in advanced NSCLC patient.

@en

The relationship between RRM1 ...... apy in advanced NSCLC patient.

@nl

type

label

The relationship between RRM1 ...... apy in advanced NSCLC patient.

@en

The relationship between RRM1 ...... apy in advanced NSCLC patient.

@nl

prefLabel

The relationship between RRM1 ...... apy in advanced NSCLC patient.

@en

The relationship between RRM1 ...... apy in advanced NSCLC patient.

@nl

P1433

Q37198266-94C811E9-FFF5-4FAD-86FF-67B82736BFB0

P1476

Q37198266-91677A03-73DD-44A9-9CDE-2F840BB299E7

P2093

Q37198266-163E7ED9-744B-4151-A88E-9E4949D237D1

Q37198266-3865D646-BFCB-46A9-BAB0-86B0CB0BACFA

Q37198266-B5953A0B-9E16-4BA4-8656-98D88AB1C0E4

Q37198266-CFC57E5E-184F-44DB-A86D-B65210656F73

P2860

Q37198266-0EE243F2-E517-4C29-BF27-BEE05E3C1767

Q37198266-1DBB91DD-2C75-445C-AF18-3BDF2C05A996

Q37198266-28900C2F-EE45-41DC-AB12-573CF0CE71F3

Q37198266-298354D8-D40E-4E8F-85BA-569DB8D694FB

Q37198266-2CDE8B0C-7698-477C-8A5F-2FED3B3B5156

Q37198266-2E7C6B38-EE74-4252-87C2-6D2B86CFCFA1

Q37198266-2EB044A5-3B42-4DDE-B828-3CE279F7F482

Q37198266-3AA98FBD-99A2-456B-A1E1-D37645D4998A

Q37198266-509B1230-87BC-4801-9BF2-721B35D37AD7

Q37198266-5A5B6B61-BE97-497D-A1D8-06221AD4ABBD

P2888

Q37198266-73F74041-8D6D-4E92-987B-A88A9792D13A

P304

Q37198266-93BCE683-20F1-4D7F-B161-04D67E4E8C27

P31

Q37198266-1691FD26-BDE1-4E84-AA93-02FBD34AD15E

P356

Q37198266-2E7C6707-0AFD-4AD4-A890-44001F5F26DD

P433

Q37198266-7838B414-FAA4-49DF-ABCE-E6EC2879041D

P478

Q37198266-2EF73278-96BE-4B30-A859-B0B058F1B3F1

P50

Q37198266-32556AD2-6654-4B1B-B50B-F964A4A1E22A

Q37198266-A04DA29D-F55D-4DEF-B850-C72489876D81

Q37198266-AEEF9504-2145-4228-9F76-467D0542D44F

Q37198266-D32CE64C-3763-4BB1-90CF-36A019FAC49E

Q37198266-DC851C8D-38D2-430D-A88F-7AA33689C078

P577

Q37198266-70BCB88C-1FF9-45C2-AEA1-B79CC37B42C7

P5875

Q37198266-D64754D6-A546-4A15-8E0D-1785CB4CFF59

P698

Q37198266-783D5334-8A5F-4655-A5ED-A6980C52DF63

P921

Q37198266-8F2DE9E5-844F-4B21-91EE-D9219E196C52

P932

Q37198266-1812E66F-0C5D-464A-AD6A-521ED5A3F7E9

P356

S12094-015-1461-1

P1433

Clinical and Translational Oncology

P1476

The relationship between RRM1 ...... rapy in advanced NSCLC patient

@en

P2093

I Homa

http://www.w3.org/2001/XMLSchema#string

J Milanowski

http://www.w3.org/2001/XMLSchema#string

M Ciesielka

http://www.w3.org/2001/XMLSchema#string

P Kozioł

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Cancer statistics, 2013

RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)

A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study.

Targeted therapy in combination with gemcitabine in non-small cell lung cancer.

Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis

P2888

s12094-015-1461-1

P304

915-924

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12094-015-1461-1

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Paweł Krawczyk

Monika Prendecka

Tomasz Powrózek

Teresa Malecka-Massalska

P577

2015-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

286544435

http://www.w3.org/2001/XMLSchema#string

P698

26650486

http://www.w3.org/2001/XMLSchema#string

P921

P932

4995236

http://www.w3.org/2001/XMLSchema#string